Clinical Trial Update: Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis Access

View source ↗

Summary

This update concerns individual patient expanded access to the Acellular Tissue Engineered Vessel (ATEV) for vascular disease and dialysis access. The program i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Vascular Disease

Drugs mentioned

• Acellular Tissue Engineered Vessel (ATEV)

Snippet

Sponsor: Humacyte, Inc. | Conditions: Vascular Diseases, End Stage Renal Disease on Dialysis | Status: TEMPORARILY_NOT_AVAILABLE